Frontiers in Pharmacology
ISSN: 1663-9812
Publisher: Frontiers Research Foundation / Frontiers Media
Publications (23)
Promotion of colorectal cancer cell death by ezetimibe via mTOR signaling-dependent mitochondrial dysfunction (2023)
Zheng Y, Yang W, Jia Y, Ji J, Wu L, Feng J, Li Y, et al.
Journal article
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing (2022)
Chen XZ, Guo R, Zhao C, Xu J, Song H, Yu H, Pilarsky C, et al.
Journal article, Review article
Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment (2021)
Thoma OM, Neurath M, Waldner M
Journal article, Review article
Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble delta 9-THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism (2021)
Iman IN, Ahmad NAZ, Yusof NAM, Talib UN, Norazit A, Kumar J, Mehat MZ, et al.
Journal article
Repeated Use of Prescription Drugs in Pediatrics: Comprehensive Overview Based on German Claims Data (2021)
Scholle O, Neubert A, Riedel O, Toni I, Haug U
Journal article
Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats (2021)
Hassan R, Sreenivasan S, Muller CP, Hassan Z
Journal article
Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease (2021)
Lueke F, Harrer DC, Menhart K, Wolff D, Holler E, Hellwig D, Herr W, et al.
Journal article
Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy (2021)
Lueke F, Harrer DC, Hahn J, Grube M, Pukrop T, Herr W, Reichle A, Heudobler D
Journal article
Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models (2021)
Haberkorn B, Fromm M, König J
Journal article, Review article
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung) (2021)
Heudobler D, Schulz C, Fischer JR, Staib P, Wehler T, Suedhoff T, Schichtl T, et al.
Journal article